JP6503626B2 - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- JP6503626B2 JP6503626B2 JP2014061251A JP2014061251A JP6503626B2 JP 6503626 B2 JP6503626 B2 JP 6503626B2 JP 2014061251 A JP2014061251 A JP 2014061251A JP 2014061251 A JP2014061251 A JP 2014061251A JP 6503626 B2 JP6503626 B2 JP 6503626B2
- Authority
- JP
- Japan
- Prior art keywords
- mass
- luliconazole
- content
- pharmaceutical composition
- solubility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 28
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 claims description 46
- 229960000570 luliconazole Drugs 0.000 claims description 46
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 27
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 26
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 15
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 15
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 claims description 15
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 14
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 14
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 14
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 14
- 229960003720 enoxolone Drugs 0.000 claims description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 13
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 13
- 229960004889 salicylic acid Drugs 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 12
- TXASKRGBMHFMPT-UHFFFAOYSA-O 1-methoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium-2-ol Chemical compound C1=[N+](C)C2=C3C=C4OCOC4=CC3=CC=C2C2=C1C(OC)=C(O)C=C2 TXASKRGBMHFMPT-UHFFFAOYSA-O 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 206010040880 Skin irritation Diseases 0.000 description 7
- 230000036556 skin irritation Effects 0.000 description 7
- 231100000475 skin irritation Toxicity 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 description 4
- 229940060184 oil ingredients Drugs 0.000 description 4
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- -1 sodium hydroxide Chemical compound 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000002163 Mesapamea fractilinea Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Description
現在、治療効果の高い抗真菌剤として新規イミダゾール系抗真菌薬であるルリコナゾールが挙げられる。ルリコナゾールは強い抗真菌活性及び皮膚角層での高い薬物貯留性により、白癬、皮膚カンジダ症及び癜風に対し、既承認薬の臨床試験における薬剤塗布期間の半分の期間で優れた臨床効果を示すことが認められている(非特許文献1)。
しかしながら、ルリコナゾールは外用剤に一般的に使用される基剤成分の水に対する溶解度が低い。また、光に対する安定性が悪く、光によって着色する。
これまでN−メチル−2−ピロリドン、炭酸プロピレンあるいはクロタミトンにルリコナゾールを溶解せしめることにより、ルリコナゾールの溶解性を向上させる技術が知られている(特許文献1)が、(a)ルリコナゾール、並びに(b)サリチル酸、イソプロピルメチルフェノール、塩化デカリニウム、塩化ベンザルコニウム、グリチルレチン酸、l−メントールあるいはdl−カンフルを含有する医薬組成物の開示はない。
(1)(a)ルリコナゾール、並びに(b)サリチル酸、イソプロピルメチルフェノール、塩化デカリニウム、塩化ベンザルコニウム、グリチルレチン酸、l−メントール及びdl−カンフルからなる群から選択される少なくとも1種の成分を含有することを特徴とする医薬組成物、
(2)水を含有する(1)に記載の医薬組成物、
(3)液剤、ローション剤、乳剤、クリーム剤、水性ゲル剤またはエアゾール剤である(1)又は(2)に記載の医薬組成物、
(4)(a)ルリコナゾールと(b)サリチル酸、イソプロピルメチルフェノール、塩化デカリニウム、塩化ベンザルコニウム、グリチルレチン酸、l−メントール及びdl−カンフルからなる群から選択される少なくとも1種の成分を混合することを特徴とする、ルリコナゾールの溶解性向上方法、
である。
実施例1〜7及び比較例1の製剤を室温で撹拌し、ルリコナゾールの性状を目視により評価した。結果を表3に示した。
実施例8、9、10及び比較例2の製剤を室温で撹拌して溶解後、3000luxの光を7日間照射し、外観性状及び波長400nmにて吸光度を測定した。結果を表4に示した。
実施例11〜23及び比較例3〜6の製剤を25℃で24時間以上撹拌した後、ろ過液中のルリコナゾールをHPLC法で定量し飽和溶解度を求めた。また、下記の式に従い、溶解度向上倍率を算出した。
溶解度向上倍率(%)=各成分添加時のルリコナゾール飽和溶解度/ルリコナゾール単独の飽和溶解度
実施例24〜28及び比較例7の製剤を25℃で24時間以上撹拌した後、ろ過液中のルリコナゾールをHPLC法で定量し飽和溶解度を求めた。また、下記の式に従い、溶解度向上倍率を算出した。
溶解度向上倍率(%)=各成分添加時のルリコナゾール飽和溶解度/ルリコナゾール単独の飽和溶解度
本発明の組成物は、ルリコナゾールの溶解度を向上することが分かった(実施例11〜28)。
以下表10に示すクリーム剤を、常法に従い、調製した。なお、表10において、数値は全て質量%を意味するものとする。
Claims (4)
- (a)ルリコナゾール、並びに(b)サリチル酸を含有することを特徴とする医薬組成物。
- (a)ルリコナゾール1質量%、(b)l−メントール、グリチルレチン酸、イソプロピルメチルフェノール、塩化ベンザルコニウム、塩化デカリニウム、及びdl−カンフルからなる群から選択される少なくとも1種の成分、及び(c)水を含む液剤又はローション剤であって、
(b)l−メントールの含有量が0.3〜3質量%、グリチルレチン酸の含有量が1質量%、イソプロピルメチルフェノールの含有量が3質量%、塩化ベンザルコニウムの含有量が0.05質量%、塩化デカリニウムの含有量が0.05〜0.5質量%、dl−カンフルの含有量が4質量%である、液剤又はローション剤。 - ルリコナゾール1質量%、及び(b)l−メントール、グリチルレチン酸、イソプロピルメチルフェノール、塩化ベンザルコニウム、及びdl−カンフルからなる群から選択される少なくとも1種の成分を含むクリーム剤であって、
(b)l−メントールの含有量が3質量%、グリチルレチン酸の含有量が1質量%、イソプロピルメチルフェノールの含有量が0.3〜3質量%、塩化ベンザルコニウムの含有量が0.05質量%、dl−カンフルの含有量が0.4〜4質量%である、クリーム剤。 - (a)ルリコナゾールと(b)サリチル酸を混合することを特徴とする、ルリコナゾールの溶解性向上方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014061251A JP6503626B2 (ja) | 2013-03-28 | 2014-03-25 | 医薬組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013067815 | 2013-03-28 | ||
JP2013067815 | 2013-03-28 | ||
JP2014061251A JP6503626B2 (ja) | 2013-03-28 | 2014-03-25 | 医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014208617A JP2014208617A (ja) | 2014-11-06 |
JP6503626B2 true JP6503626B2 (ja) | 2019-04-24 |
Family
ID=51903138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014061251A Active JP6503626B2 (ja) | 2013-03-28 | 2014-03-25 | 医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6503626B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883190B (zh) * | 2016-03-31 | 2022-07-01 | 宝丽制药股份有限公司 | 无定形化剂、包含无定形化剂而成的无定形的组合物及其使用 |
CN108143711A (zh) * | 2018-01-13 | 2018-06-12 | 天津双硕医药科技有限公司 | 一种含有卢立康唑的外用乳膏组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2645070C (en) * | 2006-03-08 | 2014-02-04 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
JP5688406B2 (ja) * | 2009-04-09 | 2015-03-25 | 株式会社ポーラファルマ | 抗真菌医薬組成物 |
EP2416757A2 (en) * | 2009-04-09 | 2012-02-15 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
JP5665495B2 (ja) * | 2010-11-16 | 2015-02-04 | 三菱電機株式会社 | データ位相同期装置およびデータ位相同期方法 |
JP6265624B2 (ja) * | 2012-05-11 | 2018-01-24 | ロート製薬株式会社 | ルリコナゾール含有外用医薬組成物 |
-
2014
- 2014-03-25 JP JP2014061251A patent/JP6503626B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014208617A (ja) | 2014-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5345937B2 (ja) | 抗真菌組成物 | |
JP5529539B2 (ja) | 医薬組成物 | |
JP6666068B2 (ja) | 外用組成物 | |
UA124181C2 (uk) | Знеболююча композиція місцевої дії | |
JPWO2009031644A1 (ja) | 抗真菌医薬組成物 | |
JP2017081901A (ja) | 水中油型乳化組成物 | |
JP6503626B2 (ja) | 医薬組成物 | |
JP6503627B2 (ja) | 医薬液体組成物 | |
JP2019006737A (ja) | 医薬組成物 | |
JP6753312B2 (ja) | 医療用皮膚外用剤 | |
JP6415156B2 (ja) | 外用組成物 | |
JP2018108955A (ja) | 水性製剤 | |
JP2007262030A (ja) | 皮膚外用剤 | |
JP5338030B2 (ja) | アダパレン含有外用剤組成物 | |
JP5233149B2 (ja) | アダパレン含有外用剤組成物 | |
JP2008184446A (ja) | アダパレン含有外用剤組成物 | |
JP6084579B2 (ja) | タクロリムスを含有する水中油型クリーム状組成物 | |
JP2017178798A (ja) | 外用組成物 | |
JP6925275B2 (ja) | 皮膚用の医薬組成物 | |
WO2007086582A1 (ja) | 22-オキサ-1α,25-ジヒドロキシビタミンD3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法 | |
JP5980171B2 (ja) | アダパレン含有外用剤組成物 | |
JP6543945B2 (ja) | 乳化組成物 | |
JP2019006738A (ja) | 医薬組成物 | |
JP2005170913A (ja) | 抗真菌性外用組成物 | |
JP2008184442A (ja) | アダパレン含有外用剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170317 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180426 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181220 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190311 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6503626 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |